![]() |
市場調查報告書
商品編碼
1497651
生技藥品市場:按來源、產品、適應症和最終用戶分類 - 2024-2030 年全球預測Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年生技藥品市場規模為4,057.6億美元,預估2024年將達4,305.9億美元,2030年將達6,263.4億美元,複合年成長率為6.39%。
生技藥品是生物醫學領域不可或缺的一部分,該領域專注於開發、製造和銷售源自生物來源的生物治療藥物,以解決各種健康狀況。疫苗、基因治療和單株抗體等產品對於治療癌症、自體免疫疾病和遺傳疾病等嚴重疾病至關重要。這些治療對於醫學機構和需要創新治療的患者至關重要。可使用生技藥品治療的慢性疾病盛行率的上升正在推動生技藥品市場的成長。醫療基礎設施投資的增加和醫療成本的上升正在擴大先進生物製藥治療的獲取範圍,並為市場成長提供了跳板。高製造成本、生物相似藥日益激烈的競爭以及分銷所需的物流(尤其是低溫運輸要求)正在阻礙市場成長。人們越來越傾向於個人化醫療,即根據個人的基因組成提供量身定做的治療方法,預計將為市場成長創造機會。開拓生物技術公司和學術機構之間的研發合作夥伴關係,以加強與生技藥品相關的創新,預計將擴大市場範圍。
主要市場統計 | |
---|---|
基準年[2023] | 4057.6億美元 |
預測年份 [2024] | 4305.9億美元 |
預測年份 [2030] | 6263.4億美元 |
複合年成長率(%) | 6.39% |
區域洞察
美洲因其強大的研究框架、大量投資和鼓勵創新的健全專利法而成為生技藥品市場的重要地區。此外,美國擁有成熟的生技藥品市場,並得到支持生物技術進步的醫療保健政策的支持。最近的進展包括 FDA 加速核准罕見疾病的生物治療方法,這表明政府的大力支持。美洲的主要企業不斷進行併購,推動該地區的成長和創新。歐盟 (EU) 對生技藥品有嚴格的監管標準,以確保治療的高度安全性和有效性。歐盟消費者重視永續且符合道德開發的產品,影響公司採用更環保的技術和實踐。歐洲藥品管理局(EMA)積極協調成員國,簡化生技藥品的核准流程,幫助新治療方法快速進入市場。中東和非洲地區充滿活力,海灣國家在醫療基礎設施和生技藥品方面進行了大量投資。消費者對生物治療的認知與接受程度不斷提高。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在生技藥品市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對生技藥品市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在生技藥品市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[180 Pages Report] The Biologics Market size was estimated at USD 405.76 billion in 2023 and expected to reach USD 430.59 billion in 2024, at a CAGR 6.39% to reach USD 626.34 billion by 2030.
Biologics are integral to the biomedical sector, focusing on developing, manufacturing, and distributing biological treatments derived from living organisms to combat various health conditions. Products, including vaccines, gene therapies, and monoclonal antibodies, are pivotal in treating serious ailments such as cancer, autoimmune disorders, and genetic diseases. These treatments are crucial in healthcare facilities and also for patients in need of innovative therapies. The rising prevalence of chronic diseases that can be treated with biologics is driving the growth of the biologics market. Increasing investments in healthcare infrastructure and an increase in healthcare spending are widening the accessibility of advanced biologic treatments, creating a platform for market growth. High manufacturing costs, rising competition from biosimilars, and demanding logistics for distribution, particularly cold chain requirements hampers the market growth. A rising inclination toward personalized medicine that provides tailored therapies based on individual genetic makeup is expected to create opportunities for market growth. Growing partnerships in research and development between biotech companies and academic entities to enhance innovation associated with biologics are anticipated to expand the market scope.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 405.76 billion |
Estimated Year [2024] | USD 430.59 billion |
Forecast Year [2030] | USD 626.34 billion |
CAGR (%) | 6.39% |
Regional Insights
The Americas represents a significant region in the biologics market, driven by strong research frameworks, substantial investments, and robust patent laws that encourage innovation. Additionally, America has a well-established biologics market supported by healthcare policies that favor biotechnological advancements. Recent trends include the FDA's accelerated approval of biological treatments for rare diseases, showcasing a significant government endorsement. Key players in the Americas are consistently engaging in mergers and acquisitions, bolstering growth and innovation in this region. The European Union exhibits stringent regulatory standards for biologics, ensuring high safety and efficacy of treatments. Consumers in the EU focus on sustainable and ethically developed products, influencing companies to adopt greener technologies and practices. The European Medicines Agency (EMA) actively coordinates across member states to streamline the approval processes for biologics, fueling rapid market entry of new therapies. The Middle East and Africa region presents a dynamic landscape, with Gulf countries investing heavily in healthcare infrastructure and the biologics sector. There is a growing awareness and acceptance of biological treatments among consumers.
Market Insights
The market dynamics represent an ever-changing landscape of the Biologics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biologics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biologics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
Biogen Inc. announced that TOFIDENCE (tocilizumab-bavi), a biosimilar to the monoclonal antibody ACTEMRA, has received U.S. FDA approval for intravenous use in treating moderately to severely active rheumatoid arthritis, as well as polyarticular and systemic juvenile idiopathic arthritis. This marks the first tocilizumab biosimilar cleared in the United States, potentially offering significant cost savings and wider therapy accessibility. The approval is pivotal, considering the annual 10%-25% increase in spending on autoimmune treatments over the last decade. [Published On: 2023-09-29]
Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
Eli Lilly invested in its biologics production facility, which is currently under construction in Raheen, Limerick County, Ireland. Eli Lilly injected an additional USD 500 million into the site, elevating its total expenditure to approximately 927 million USD 1 billion. [Published On: 2023-03-26]
Sandoz Announces Major Investment in New Biologics Facility in Slovenia
Sandoz invested over USD 400 million to construct a new biologics production facility in Lendava, Slovenia. This strategic development is aimed at bolstering the company's biosimilar portfolio. The construction underscores Sandoz's commitment to expanding its global presence while significantly contributing to local economic growth. [Published On: 2023-03-10]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biologics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..
Market Segmentation & Coverage